INS and type 2 diabetes mellitus: A 2015 pilot study evaluated the use of BC-QR in seven 30-65-year-old T2DM patients on metformin (1-2 g/day) and high-dose basal-bolus insulin (total daily insulin dose (TDID)≥65 U/day) with HbA1C between 7.5% and 12.0% for 24 weeks [23].